Long-term safety evaluation of Daxocox(®) tablets (enflicoxib) in dogs after weekly oral administrations for seven months

BACKGROUND: Daxocox® [Ecuphar/Animalcare Group] contains the selective COX-2 inhibitor enflicoxib, approved in the EU for the treatment of pain and inflammation associated with osteoarthritis in dogs. The safety of Daxocox(®) was evaluated in a target animal safety study: Groups of 4 dogs per sex ea...

Descripción completa

Detalles Bibliográficos
Autores principales: Homedes, Josep, Salichs, Marta, Guzman, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173827/
https://www.ncbi.nlm.nih.gov/pubmed/34082759
http://dx.doi.org/10.1186/s12917-021-02910-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173827/
https://www.ncbi.nlm.nih.gov/pubmed/34082759
http://dx.doi.org/10.1186/s12917-021-02910-0

Ejemplares similares